Body produces white blood cells (leukocytes), which help fight bacterial infections, viruses and fungi. If your child has too few or too many white blood cells, in general, here's what it means: Low white blood cell count (leukopenia) means having too few leukocytes circulating in the blood. A long-term low white blood cell count increases the risk of infections and may be caused by a number of different diseases and conditions. High white blood cell count (leukocytosis) means having too many leukocytes circulating in the blood, usually from having an infection. A number of different diseases and conditions may cause a long-term high white blood cell count.
It is considered to be the most successful drug therapy for severe sickle cell disease (SCD). Nevertheless, questions remain regarding its benefits in very young children and its role in the prevention of cerebrovascular events. There were 127 SCD patients treated with no attempt to reach maximal tolerated doses who entered the Belgian Registry: 109 for standard criteria and 18 who were at risk of stroke only. During 426 patient-years of follow-up for patients with standard criteria, 3.3 acute chest syndromes, 1.3 cerebrovascular events, and 1.1 osteonecrosis per 100 patient-years were observed.
Treatments for white blood cell disorders depend on several factors, including: The type of disorder, The extent of the disorder, Your child’s overall health, Your child’s response to treatment, Your preferences Our treatments for your child’s white blood cell disorder may include: Chemotherapy, Radiation, Antibiotics, Colony-stimulating factors (these increase the body’s production of blood cells), Drugs to suppress the immune system Stem cell transplantation may be useful for some types of severe white blood cell disorders, particularly those caused by bone marrow problems
From 1978 to 1988. Patients were followed for an average of 5.2 ± 2.0 years. Age-specific prevalence and incidence rates of CVA in patients with the common genotypes of sickle cell disease were determined, and the effects of hematologic and clinical events on the risk of CVA were analyzed. The highest rates of prevalence of CVA (4.01%) and incidence (0.61 per 100 patient-years) were in sickle cell anemia (SS) patients, but CVA occurred in all common genotypes. The incidence of infarctive CVA was lowest in SS patients 20 to 29 years of age and higher in children and older patients. Conversely, the incidence of hemorrhagic stroke in SS patients was highest among patients aged 20 to 29 years.